Scientists have made 'exciting,' patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. This emerging technology holds ...
Morgan Stanley has recently raised Gilead Sciences Inc (GILD) stock rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc ...
With incoming president Donald Trump threatening a trade war with China, experts told BioSpace that the new administration ...
Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...
Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
Two moon landers, one from Japan's ispace and another from U.S. space firm Firefly, began their journeys into space on Wednesday (January 15) with SpaceX's unusual double moonshot launch, underscoring ...
The colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...
Major moves in the pharmaceutical industry include Ownership Matters recommending support for the Chemist Warehouse-Sigma Healthcare merger, J&J's potential bid for Intra-Cellular Therapies, and ...
Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback